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To the editor: 
We read with interest the article by de Jong and col-
leagues, who provide an initial insight into European 
hospital preparedness level for the admission of a 
patient with Ebola virus disease (EVD) [1].
In the past, the rare imported cases of Ebola and 
Marburg in western European countries and the United 
States were managed in high-level isolation units 
(HLIUs) [2]. Subsequently, reported experiences indi-
cate that strict contact-droplet isolation is enough 
for preventing transmission. From this hypothesis, 
the idea may derive that HLIUs are not strictly neces-
sary for the management of EVD patients, who may be 
safely managed in non-specialised hospitals, as sug-
gested by some international recommendations elabo-
rated during the current Ebola outbreak in West Africa 
[3,4]. Even if we concur that strict contact-droplet iso-
lation is enough to prevent transmission during routine 
care, we believe that HLIUs should have a key role in 
EVD containment in countries where such facilities are 
available. An HLIU is a healthcare facility specifically 
designed to provide safe, secure, high-quality, and 
appropriate care, with optimal infection containment 
and infection prevention and control procedures, for a 
single patient or a small number of patients who have, 
or who may have, a highly infectious disease [5].
In hospitals, breaches in infection control may occur; 
many healthcare associated infections could be pre-
vented by standard precautions and contact isolation 
measures, but despite this, they continue to hit thou-
sands of patients and to increase health-related costs 
[6]; measures for preventing needlestick and sharp 
injuries are well-known, but many of these accidents 
occur every day; hand hygiene alone may prevent 
many infections, but this simple procedure is often 
poorly applied [6]. We believe that such breaches are 
not acceptable when managing a disease with 50% of 
case fatality rate such as EVD. Data from de Jong and 
colleagues, reporting that practical exercises have 
been performed in 28.4% of responding hospitals 
only [1], as well as the secondary transmissions that 
occurred in Spain and the United States, reinforce this 
position.
Indeed, establishing precautions is not equal to their 
adherence. Well-trained staff, awareness about per-
sonal protective equipment and other infection control 
procedures, continuous practice, appropriate super-
vision, and adequate logistics are needed; in other 
words, an established ‘infection control culture and 
practice’. Moreover, rooms with special technical air-
handling features are necessary for aerosol-producing 
procedures [7].
We believe that this unique combination of technical 
and logistic equipment, well-trained and experienced 
staff, and long-term established and updated proce-
dures, is available within HLIUs only, thereby repre-
senting the safest place to manage EVD.
In Europe, an assessment of isolation capabilities for 
the management of highly infectious diseases was 
performed in 2009–2010 within the European Network 
for Infectious Diseases/European Network for Highly 
Infectious Diseases (EUNID/EuroNHID) projects coordi-
nated by the National Institute for Infectious Diseases 
‘Lazzaro Spallanzani’ in Italy [8]. The EuroNHID 
Consortium currently includes  47 isolation facilities 
identified by the national health authorities as refer-
ral centres for highly infectious diseases (including 
EVD), in 20 countries (Austria, Bulgaria, Belgium, 
Denmark, Finland, France, Germany, Greece, Hungary, 
Ireland, Italy, Luxembourg, Malta, Norway, Poland, 
Portugal, Spain, Slovenia, Sweden and the United 
Kingdom). The survey results are being updated in 
2014: complete data are available from 12 countries; 
from the remaining eight countries, partial data are 
available. According to currently available data, among 
2 www.eurosurveillance.org
the 47 isolation facilities 17 HLIUs are present in nine 
European countries, with at least 92 beds available, 
57 of which with intensive care capacity. Additional 
capacity may be present in other countries not partici-
pating to EuroNHID Consortium. This bed capacity (not 
expected to change significantly after the collection of 
pending data) is surely enough to effectively manage 
Ebola patients in Europe, in the current epidemiologi-
cal situation.
In conclusion, we strongly believe that HLIUs should 
play a crucial role in management of patients, and pre-
paredness plans should include referral of EVD patients 
to these facilities as early as possible.
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